Pharmacogenomics in Pediatric Oncology: Review of Gene—Drug Associations for Clinical Use

International Journal of Molecular Sciences

Vid Mlakar¹  Chakradhara Rao Satyanarayana Uppugunduri¹  Patricia Huezo-Diaz Curtis¹  Marc Ansari¹  Maja Krajinovic² 

[1] Cansearch Research Laboratory, Geneva University Medical School, Avenue de la Roseraie 64, 1205 Geneva, Switzerland;Charles-Bruneau Cancer Center, Centre hospitalier universitaire Sainte-Justine, 4515 Rue de Rouen, Montreal, QC H1V 1H1, Canada;

关键词: pediatrics;    pharmacogenomics;    PharmGKB;    thiopurine;    cisplatin;    methotrexate;    cyclophosphamide;    irinotecan;   

DOI  :  10.3390/ijms17091502

来源: DOAJ

【 摘 要 】

During the 3rd congress of the European Society of Pharmacogenomics and Personalised Therapy (ESPT) in Budapest in 2015, a preliminary meeting was held aimed at establishing a pediatric individualized treatment in oncology and hematology committees. The main purpose was to facilitate the transfer and harmonization of pharmacogenetic testing from research into clinics, to bring together basic and translational research and to educate health professionals throughout Europe. The objective of this review was to provide the attendees of the meeting as well as the larger scientific community an insight into the compiled evidence regarding current pharmacogenomics knowledge in pediatric oncology. This preliminary evaluation will help steer the committee’s work and should give the reader an idea at which stage researchers and clinicians are, in terms of personalizing medicine for children with cancer. From the evidence presented here, future recommendations to achieve this goal will also be suggested.

【 授权许可】

Unknown